People, studies, knowledge and standards in a single navigable graph. Four radars that intersect with one another, continuously updated and defensible to compliance.
The industry has sources to spare and too little perspective. No one today sees people, studies, knowledge and standards for what they are: nodes in the same graph. Pharma Mapping isn't another database: it's the map that connects the four dimensions of a therapeutic area and makes them navigable.
Each radar answers a critical question about the clinical ecosystem of a therapeutic area. They are delivered as a narrated monthly report and as a dashboard view — by therapeutic area, by geography, by function within your team.
Who the influential people (Digital Opinion Leaders) in a field are, and why. Profiling, multidimensional scoring, collaboration networks, trial activity and momentum — distinguishing emerging from established leaders.
What future evidence is being built. Mapping of clinical trials by therapeutic area, phase, sponsor, geography and status across LATAM, with competitive intelligence and automatic cross-referencing of PIs with the DOL Radar.
What is known today and where the gaps are. Publication volume and trends, top papers and journals, emerging topics, evidence gaps and real LATAM output — including SciELO and Lilacs, not just PubMed.
What the current standard of care is. Clinical guidelines in force, societies and committees, regulatory statements (ANMAT, COFEPRIS, ANVISA, EMA, FDA, PAHO/WHO), approvals and labeling changes.
People, studies, knowledge and standards aren't silos: they are nodes in a single graph. That intersection is the moat —impossible to replicate by buying standalone reports— and the reason Pharma Mapping is sold as a platform, not as four products.
An opinion leader who joins a Phase 3 trial as PI: an early signal that the therapeutic area is gaining weight for that person. The system detects it and flags it.
When a guideline is updated, you see who signed it, their lines of work and their affiliations. You know why the standard changed, not just that it changed.
A meta-analysis that shifts the balance of evidence signals which guidelines are due for an update and which committees control them.
The results paper is linked to the registered trial: full traceability across the evidence chain.
Not just PubMed. We integrate SciELO, Lilacs and the national registries (ReBEC, ReNIS, REPEC and more). We see what is published from and about the region, where everyone else has blind spots.
The graph cross-references people, studies, knowledge and standards automatically. That synergy is the defensible asset: it can't be reproduced by buying standalone datasets.
Only public sources licensed for commercial use. Factual metadata, never restricted content. Zero contact data. Every score reproducible, with an immutable audit log. An easy sell to compliance.
A daily incremental pipeline and a monthly AI-narrated report built on precomputed KPIs. Always-fresh intelligence, with no heavy manual work and at marginal cost per therapeutic area.
Identify and prioritize the right DOLs by therapeutic area and geography, tell emerging from established leaders, and anticipate which committees are moving the standard of care so you get there sooner and better prepared.
Track guidelines, approvals and labeling changes across AR/MX/BR, map evidence gaps and build the value dossier knowing what future evidence is on the way.
See the trial landscape by sponsor within an indication, spot early competitor moves and read their bets through comparators and endpoints.
Equip your MSLs with a living map of the field: who is publishing what, who is joining which trial, what is being discussed this month. Better-informed conversations, data-driven planning.
Pharma Mapping was designed to clear the compliance conversation before it even starts. This is what makes it an easy sell.
OpenAlex, PubMed, ORCID, Crossref, ClinicalTrials.gov, openFDA, SciELO, Lilacs, Europe PMC, national registries and official regulator websites.
Title, authors, date, DOI, committee, link. Full content only from open-license sources (WHO, NICE, PAHO, USPSTF), with attribution.
We don't sell leads, emails, phone numbers or outreach lists. We sell aggregated, structured intelligence.
Every score is reproducible and there is an immutable audit log. If you ask “how did you arrive at this?”, there's an answer.
We don't access paywalled content without a license. We don't scrape private or login-protected sites. We don't reproduce copyrighted content. We don't predict individual prescribing or analyze specific physician behavior.
Each exclusion is a layer of legal protection for your company — and the reason your compliance team can say yes.
A low-risk adoption model: you try it with a one-off report, stay on with the subscription and the dashboard, and expand to the full platform once the graph has become indispensable.
One report from one radar, for one therapeutic area and geography. The first frictionless “yes.”
Ongoing access to one or more radars, with monthly reports, alerts and a dashboard.
All four radars and the connections between them: the synergy you can't buy piece by piece.
Pricing axes: by radar · by therapeutic area · by geography (AR / MX / BR / LATAM) · by depth (report → dashboard → platform + API) · by client tier.
Sources, integration and pricing, answered up front. If your question isn't here, we'll answer it in the demo using a real therapeutic area from your portfolio.
Book a demo: we'll show you the four radars intersecting on a real therapeutic area from your portfolio, walk you through a narrated sample report, and work out with you where it makes sense to start.
carol.calva@mednet.solutions · +52 55 2966 2204 · Mexico City · Buenos Aires
